Fatty Acid Remodeling Seen in T2DM Remission Post Bariatric Sx

Share this content:
Fatty Acid Remodeling Seen in T2DM Remission Post Bariatric Sx
Fatty Acid Remodeling Seen in T2DM Remission Post Bariatric Sx

MONDAY, Aug. 28, 2017 (HealthDay News) -- Remission of type 2 diabetes (T2D) following biliopancreatic diversion with duodenal switch (DS) is associated with increased disposal of triglycerides (TG) and acylcarnitine production during lipid overload, according to a study published online Aug. 23 in Diabetes.

Thomas Grenier-Larouche, from the Université de Sherbrooke in Canada, and colleagues examined the longitudinal contribution of adipocyte size reduction and fatty acid metabolic handling to T2D remission following bariatric surgery.

The researchers found that during intravenous lipid overload, severely obese participants with T2D displayed hypertriglyceridemia and excessive systemic lipolysis. The whole-body glycerol turnover was normalized three days after DS, and was associated with lower homeostatic model assessment of insulin resistance index. An excess weight loss of 84 percent was achieved on average 12 months after DS. In T2D, smaller subcutaneous adipocyte size predicted a better glycemic control. TG disposal and acylcarnitine production during lipid overload correlated with improvement in weight loss and muscle insulin sensitivity. Systemic non-esterified fatty acid fluxes and spillover remained similar, indicating that the increased storage capacity compensated the decrease in fat mass during weight loss.

"In conclusion, T2D remission after DS is mainly associated with greater circulating TG disposal, lower systemic lipolysis, and better fatty acid handling by lean tissues," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »